NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis $1.02 +0.01 (+0.99%) (As of 12:49 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Adial Pharmaceuticals Stock (NASDAQ:ADIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adial Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.00▼$1.0250-Day Range$0.94▼$1.1752-Week Range$0.77▼$4.17Volume22,879 shsAverage Volume2.78 million shsMarket Capitalization$6.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAdial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Read More… Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Adial Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks14th Percentile Overall ScoreADIL MarketRank™: Adial Pharmaceuticals scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Adial Pharmaceuticals.Read more about Adial Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.79) to ($1.51) per share.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adial Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.81% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently decreased by 34.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.81% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently decreased by 34.19%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.24% of the stock of Adial Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Adial Pharmaceuticals is held by institutions.Read more about Adial Pharmaceuticals' insider trading history. Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Stock News HeadlinesShort Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 34.2%October 27, 2024 | americanbankingnews.comAdial Pharmaceuticals to Present at the 2024 ThinkEquity ConferenceOctober 23, 2024 | globenewswire.comBlackrock’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… November 4, 2024 | Crypto 101 Media (Ad)EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder CandidateOctober 18, 2024 | finance.yahoo.comAdial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of RecoveryOctober 16, 2024 | finance.yahoo.comAdial Pharmaceuticals (NASDAQ:ADIL) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comMaxim Group Keeps Their Hold Rating on Adial Pharmaceuticals (ADIL)September 21, 2024 | markets.businessinsider.comAdial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use DisorderSeptember 19, 2024 | globenewswire.comSee More Headlines ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed this year? Adial Pharmaceuticals' stock was trading at $1.86 at the beginning of 2024. Since then, ADIL stock has decreased by 45.2% and is now trading at $1.02. View the best growth stocks for 2024 here. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.39) by $0.20. When did Adial Pharmaceuticals' stock split? Adial Pharmaceuticals shares reverse split on the morning of Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and General Electric (GE). Company Calendar Last Earnings8/13/2024Today11/04/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-183.64% Return on Assets-160.59% Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.41Miscellaneous Outstanding Shares6,410,000Free Float6,070,000Market Cap$6.54 million OptionableNo Data Beta1.29 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report This page (NASDAQ:ADIL) was last updated on 11/4/2024 by MarketBeat.com Staff From Our PartnersCRUSHED: How Biden's Replacement Will Devastate Your 401(k)!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a ...Golden Crest | Sponsored[Charles Payne Live Event] Click to Confirm Your RSVPThe Blueprint to Protect Your Portfolio Charles Payne reveals a strategy few investors know about Unstoppable Prosperity | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredA new way to play the AI boom (act before November 19)There's a new way to play the $15 trillion AI boom. And it's so simple - you can do it right now with as li...Behind the Markets | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.